Cipla gets USFDA EIR for Indore facility

Published On 2022-09-24 05:37 GMT   |   Update On 2022-09-24 05:37 GMT
Advertisement

Mumbai: Pharma major, Cipla, has recently announced that the Company has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Indore plant, indicating the closure of the inspection.

The inspection was conducted from 27th June 2022 to 1st July 2022.

"Further to the intimation dated 4th July 2022, this is to inform you that following the product-specific PreApproval Inspection (PAI) by the United States Food and Drug Administration (USFDA) at the Indore plant from 27th June 2022 to 1st July 2022, the Company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection," the Company stated in a BSE filing,

Advertisement

Medical Dialogues team had earlier reported that the USFDA had issued two observations after a Pre Approval Inspection at the Company's Indore plant.

Read also: Cipla Indore plant gets 2 USFDA observations

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.

Read also: Cipla Cancer drug Lenalidomide bags USFDA okay

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News